BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer 2015;15:184. [PMID: 25879531 DOI: 10.1186/s12885-015-1186-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Abdu S, Juaid N, Amin A, Moulay M, Miled N. Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights. Antioxidants 2022;11:1645. [DOI: 10.3390/antiox11091645] [Reference Citation Analysis]
2 Anschlag A, Greene BH, KÖnneker L, Luster M, Nagarajah J, WÄchter S, Wunderlich A, Pfestroff A. Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro. In Vivo 2021;35:721-9. [PMID: 33622865 DOI: 10.21873/invivo.12313] [Reference Citation Analysis]
3 Kim J, Park JH, Park SK, Hoe HS. Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice. Front Immunol 2021;12:684344. [PMID: 34122447 DOI: 10.3389/fimmu.2021.684344] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Jeong C, Lee J, Yoon H, Ha J, Kim MH, Bae JS, Jung CK, Kim JS, Kang MI, Lim DJ. Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis. Cancers (Basel) 2021;13:811. [PMID: 33671989 DOI: 10.3390/cancers13040811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kim SY, Kim SM, Chang H, Chang HS, Park CS, Lee YS. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo. Head Neck 2020;42:3678-84. [PMID: 32896015 DOI: 10.1002/hed.26431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wang X, Gupta P, Jramne Y, Danilenko M, Liu D, Studzinski GP. Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. Oncotarget 2020;11:3129-43. [PMID: 32913557 DOI: 10.18632/oncotarget.27687] [Reference Citation Analysis]
7 Ansar S, Vetrivel U. KinomeRun: An interactive utility for kinome target screening and interaction fingerprint analysis towards holistic visualization on kinome tree. Chem Biol Drug Des 2020;96:1162-75. [PMID: 32418310 DOI: 10.1111/cbdd.13705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Li S, Dong S, Xu W, Jiang Y, Li Z. Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer. Front Pharmacol 2019;10:1676. [PMID: 32116677 DOI: 10.3389/fphar.2019.01676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ali MY, Tariq I, Ali S, Amin MU, Engelhardt K, Pinnapireddy SR, Duse L, Schäfer J, Bakowsky U. Targeted ErbB3 cancer therapy: A synergistic approach to effectively combat cancer. Int J Pharm 2020;575:118961. [PMID: 31846731 DOI: 10.1016/j.ijpharm.2019.118961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu D, Tian W, Li J, Zhang Q, Wang H, Zhang L, Xie Z, Ji A, Li Y. Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway. Mol Biol Rep 2019;46:2665-78. [PMID: 31028568 DOI: 10.1007/s11033-019-04698-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Wu D, Liu Z, Li J, Zhang Q, Zhong P, Teng T, Chen M, Xie Z, Ji A, Li Y. Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway. Cancer Cell Int 2019;19:43. [PMID: 30858760 DOI: 10.1186/s12935-019-0762-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
12 Ke Y, Xiang C. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy. Int J Nanomedicine 2018;13:8339-54. [PMID: 30584304 DOI: 10.2147/IJN.S187240] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
13 Wu WD, Chen PS, Omar HA, Arafa EA, Pan HW, Jeng J, Hung JH. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Sci Rep 2018;8:12914. [PMID: 30150684 DOI: 10.1038/s41598-018-31209-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
14 Wang Z, Liu F, Gong Y, Huang T, Zhang X, Huang X. Antiarthritic Effects of Sorafenib in Rats with Adjuvant-Induced Arthritis: ANTIARTHRITIC EFFECTS OF SORAFENIB. Anat Rec 2018;301:1519-26. [DOI: 10.1002/ar.23856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Feng XQ, Rong LW, Wang RX, Zheng XL, Zhang L, Zhang L, Lin Y, Wang X, Li ZP. Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. Oncol Lett 2018;16:648-53. [PMID: 29928452 DOI: 10.3892/ol.2018.8640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
16 Cirello V, Vaira V, Grassi ES, Vezzoli V, Ricca D, Colombo C, Bosari S, Vicentini L, Persani L, Ferrero S, Fugazzola L. Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors. Oncotarget 2017;8:9752-66. [PMID: 28039458 DOI: 10.18632/oncotarget.14187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
17 Liu Y, Qin Z, Cai L, Zou L, Zhao J, Zhong F. Selection of internal references for qRT-PCR assays of human hepatocellular carcinoma cell lines. Biosci Rep 2017;37:BSR20171281. [PMID: 29180379 DOI: 10.1042/BSR20171281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
18 Gigliotti CL, Ferrara B, Occhipinti S, Boggio E, Barrera G, Pizzimenti S, Giovarelli M, Fantozzi R, Chiocchetti A, Argenziano M, Clemente N, Trotta F, Marchiò C, Annaratone L, Boldorini R, Dianzani U, Cavalli R, Dianzani C. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. Drug Deliv 2017;24:670-80. [PMID: 28368209 DOI: 10.1080/10717544.2017.1303856] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
19 Lee H, Shin EA, Lee JH, Ahn D, Kim CG, Kim J, Kim S. Caspase inhibitors: a review of recently patented compounds (2013-2015). Expert Opinion on Therapeutic Patents 2018;28:47-59. [DOI: 10.1080/13543776.2017.1378426] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
20 Martens S, Jeong M, Tonnus W, Feldmann F, Hofmans S, Goossens V, Takahashi N, Bräsen JH, Lee EW, Van der Veken P, Joossens J, Augustyns K, Fulda S, Linkermann A, Song J, Vandenabeele P. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death Dis 2017;8:e2904. [PMID: 28661484 DOI: 10.1038/cddis.2017.298] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
21 Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Stem Cell Res Ther 2017;8:119. [PMID: 28545562 DOI: 10.1186/s13287-017-0573-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
22 Park KC, Kim SM, Jeon JY, Kim BW, Kim HK, Chang HJ, Lee YS, Kim SY, Choi SH, Park CS, Chang HS. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer. Neoplasia 2017;19:145-53. [PMID: 28142087 DOI: 10.1016/j.neo.2016.12.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
23 Pehserl AM, Ress AL, Stanzer S, Resel M, Karbiener M, Stadelmeyer E, Stiegelbauer V, Gerger A, Mayr C, Scheideler M, Hutterer GC, Bauernhofer T, Kiesslich T, Pichler M. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. Int J Mol Sci 2016;17:E2011. [PMID: 27916938 DOI: 10.3390/ijms17122011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
24 Eckhardt S, Hoffmann S, Damanakis AI, Di Fazio P, Pfestroff A, Luster M, Wunderlich A, Bartsch DK. Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature. Int J Surg Case Rep 2016;25:174-8. [PMID: 27379749 DOI: 10.1016/j.ijscr.2016.06.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Broecker-Preuss M, Becher-Boveleth N, Müller S, Mann K. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells. Cancer Cell Int 2016;16:27. [PMID: 27042160 DOI: 10.1186/s12935-016-0303-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
26 Park CH, Cho SY, Ha JD, Jung H, Kim HR, Lee CO, Jang IY, Chae CH, Lee HK, Choi SU. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells. BMC Cancer. 2016;16:35. [PMID: 26801760 DOI: 10.1186/s12885-016-2058-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
27 Lin MT, Lin CL, Lin TY, Cheng CW, Yang SF, Lin CL, Wu CC, Hsieh YH, Tsai JP. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumour Biol 2016;37:6987-96. [PMID: 26662956 DOI: 10.1007/s13277-015-4526-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
28 Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, Larijani B. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Tumour Biol 2016;37:1299-308. [PMID: 26289851 DOI: 10.1007/s13277-015-3923-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
29 Broecker-Preuss M, Viehof J, Jastrow H, Becher-Boveleth N, Fuhrer D, Mann K. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res 2015;34:69. [PMID: 26198850 DOI: 10.1186/s13046-015-0186-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]